Activating mutations in PTPN11, encoding the cytosolic protein tyrosine phosphatase SHP2, result in developmental disorders and act as oncogenic drivers in patients with hematologic cancers. Here, PTPN11 is linked to hematopoietic and lymphoid cell neoplasm.